SRRK Scholar Rock Holding52.12-3.29 (-5.9%)
After Hours Gainer
SRRK Scholar Rock Holding55.41-0.26-0.5%
After Hours:61.97+6.56 (+11.8%)
Scholar Rock Announces FDA Approval of ISEMBYLD (apitegromab-mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
Business WireFri, 11-Sep 6:25 PM
After Hours:63.33+7.92 (+14.3%)
SRRK Scholar Rock Holding60.44+2.19 (+3.8%)
SRRK Scholar Rock Holding50.87+0.21 (+0.4%)
SRRK Scholar Rock Holding52.58-1.46 (-2.7%)